Using Wegovy for Weight Loss: What Actually Happens

How does Wegovy actually change the way you feel about food?

The simplest way to understand semaglutide is that it amplifies signals your body already uses. GLP-1 (glucagon-like peptide-1) is released naturally after eating. It tells the brain you are full, slows gastric emptying, and reduces the drive to keep eating. Wegovy binds to GLP-1 receptors and keeps that signal active for far longer than the hormone manages on its own.

In practical terms, people using Wegovy often describe smaller appetite, less interest in food between meals, and an earlier sense of satisfaction during a meal. That shift is not willpower, it is a measurable physiological change. Cravings for high-fat or high-sugar foods can also reduce, though this varies between individuals.

The NHS medicines page for semaglutide explains the mechanism in plain language and is worth reading alongside the patient information leaflet that comes with your pen. Understanding what the medicine is doing makes it easier to work with it rather than around it, for instance, choosing protein-rich meals that complement the appetite effect rather than skipping meals entirely, which can worsen nausea.

For more background on the medicine itself, our semaglutide overview covers the clinical picture in more detail.

What does the evidence say about how much weight people lose using Wegovy?

The headline figure comes from the STEP 1 trial: roughly 15% average body-weight reduction over 68 weeks in adults without type 2 diabetes, alongside a reduced-calorie diet and increased physical activity. That is an average, some participants lost considerably more, others less. A question our prescribers hear most weeks is whether the trial results translate to real life, and the honest answer is: broadly yes, but individual response varies, and stopping treatment typically leads to weight returning.

The STEP 1 results, published in the New England Journal of Medicine, involved nearly 2,000 adults and are the evidence base NICE used when recommending Wegovy for NHS use under TA875. The higher 7.2 mg dose (approved by the MHRA in April 2026) has shown around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide. For a fuller look at what weight loss on Wegovy tends to look like month by month, our Wegovy weight-loss results page covers the evidence in more depth.

It is also worth knowing that Wegovy works best alongside genuine lifestyle changes. The trial participants followed structured support, the medicine provides a significant biological advantage, but diet quality and activity still shape the outcome.

Who is Wegovy suitable for, and are there situations where it is not recommended?

The UK licence covers adults with a BMI of 30 or above, or those with a BMI from 27 who have at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or pre-diabetes. Lower BMI thresholds of 2.5 kg/m² apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. BMI alone does not determine suitability, your full medical history matters.

Wegovy is not recommended during pregnancy, breastfeeding, or if you are actively trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a history of pancreatitis need a careful prescriber conversation before starting. Certain gut conditions and kidney function considerations also affect suitability.

If you are already on treatment elsewhere and considering moving to a regulated provider, what to know before using semaglutide is a practical guide to that process. The NICE appraisal of Wegovy (TA875) sets out the clinical criteria used by NHS services, which differ from private eligibility thresholds, worth understanding if you are comparing routes. Private eligibility through a regulated online pharmacy follows the licensed indications in the SmPC rather than NICE's NHS commissioning criteria.

What do people find hardest about using Wegovy, and how do most people get through it?

The most commonly reported challenges are gastrointestinal: nausea, constipation, loose stools, reflux, or burping, particularly in the first weeks or after a dose step-up. For most people these are mild to moderate and ease within a fortnight. A small number find them persistent enough to affect the titration schedule, that is a conversation to have with your prescriber rather than a reason to stop unilaterally.

Practical things that tend to help: eating smaller meals, avoiding very rich or spicy food during the first weeks of a new dose, staying well hydrated, and not rushing the titration if your body needs longer at a lower step. Your prescriber decides the pace, not the calendar. Side effects that are severe, persistent, or include acute abdominal pain radiating to the back should prompt urgent medical attention, the MHRA has highlighted pancreatitis as an infrequent but serious risk with GLP-1 medicines, and it warrants prompt assessment. Our guide to using Wegovy covers how to manage the titration schedule and what to do if side effects make it harder to follow.

Understanding the cost of private treatment is a reasonable part of planning. Our Wegovy pricing page explains what is included in a legitimate private prescription service, which matters for comparing options fairly. Men sometimes find the experience differs in detail from published averages, Wegovy for men addresses some of those specifics. And if you want to explore other licensed weight-loss options alongside Wegovy, our treatment overview sets them out clearly.